Table 4 Thalidomide in patients with... | American Society of Hematology

Table 4

Thalidomide in patients with newly diagnosed MM

Regimen	No. patients	CR, %	Greater than PR, %	PFS/EFS/TTP, %	OS, %	Reference
Dexamethasone
TD	235	5	49	50 at 17 mo	ND	52 *†
TD	103	4	63	50 at 22 mo	72 at 24 mo	31 *
TD	100	10	76	ND	ND	32
TD	50	ND	64	ND	ND	34
TD	100	ND	25‡	ND	ND	33 *
TD	136	14	68	50 at 25 mo	50 at 45 mo	35 *†
Melphalan
MPT	129	16	76	54 at 24 mo	80 at 36 mo	37 *
MPT	125	13	76	50 at 28 mo	50 at 52 mo	38 *
MPT	113	7	62	50 at 24 mo	50 at 45 mo	39 *
Doxorubicin
ThaDD	50	34	88	57 at 36 mo	74 at 36 mo	44
TAD	193	ND	79-81	ND	ND	53 *
DVd-T	55	36	83	50 at 28 mo	ND	25
T-VAD doxil	117	15	81	59 at 24 mo	77 at 24 mo	45 *
T-VAD doxil	39	10	74	55 at 22 mo	74 at 22 mo	40
Cyclophosphamide, CTD	27	15	89	ND	ND	47

Regimen	No. patients	CR, %	Greater than PR, %	PFS/EFS/TTP, %	OS, %	Reference
Dexamethasone
TD	235	5	49	50 at 17 mo	ND	52 *†
TD	103	4	63	50 at 22 mo	72 at 24 mo	31 *
TD	100	10	76	ND	ND	32
TD	50	ND	64	ND	ND	34
TD	100	ND	25‡	ND	ND	33 *
TD	136	14	68	50 at 25 mo	50 at 45 mo	35 *†
Melphalan
MPT	129	16	76	54 at 24 mo	80 at 36 mo	37 *
MPT	125	13	76	50 at 28 mo	50 at 52 mo	38 *
MPT	113	7	62	50 at 24 mo	50 at 45 mo	39 *
Doxorubicin
ThaDD	50	34	88	57 at 36 mo	74 at 36 mo	44
TAD	193	ND	79-81	ND	ND	53 *
DVd-T	55	36	83	50 at 28 mo	ND	25
T-VAD doxil	117	15	81	59 at 24 mo	77 at 24 mo	45 *
T-VAD doxil	39	10	74	55 at 22 mo	74 at 22 mo	40
Cyclophosphamide, CTD	27	15	89	ND	ND	47

ThaDD indicates thalidomide-pegylated liposomal doxorubicin-dexamethasone; T-VAD doxil, thalidomide-vincristine-pegylated lyposomal doxorubicin; and ND, not determined.

Randomized trial.

†

Updated information was presented at the American Society of Clinical Oncology and European Hematology Association Congress.

‡

Very good partial response rate.

View Large

This Feature Is Available To Subscribers Only